Literature DB >> 6244090

Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.

K K Chan, R T Chlebowski, M Tong, H S Chen, J F Gross, J R Bateman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6244090

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  21 in total

1.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 2.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system.

Authors:  T Iwamiya; S Sawada; Y Ohta
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

7.  The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

Authors:  N L Harris; D E Brenner; L B Anthony; J C Collins; S Halter; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report.

Authors:  K Lee; K Chan; W T Leung; N W Leung; S Ho; M Chan; C C Lau; M Tao; W Y Lau; W Shiu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

9.  Transcatheter hepatic arterial chemoembolization using epirubicin-lipiodol: experimental and pharmacological evaluation.

Authors:  S Kobayashi; Y Narimatsu; K Ogawa; S Hashimoto; S Nakatsuka; H Miura; H Ohzono; W J Ka; K Ido; K Hiramatsu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Protein binding of anthraquinone glycosides, with special reference to adriamycin.

Authors:  S Eksborg; H Ehrsson; B Ekqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.